Clinical Trials
24 articles in the Clinical Trials category
UK MHRA approves orforglipron for private prescriptions
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorised orforglipron for private prescription. This decision allows the oral GLP-1 receptor agonist to be prescribed outside the NHS. The authorisation was reported by pharmaphorum on August 24, 2026.
5 min read
Meant Launches LegitScript-Certified GLP-1 Telehealth Platform with Coaching
Meant has introduced a new telehealth platform for GLP-1 therapies that has earned LegitScript certification. The platform combines medical oversight with personalized coaching to support patients using GLP-1 medications. This launch marks a step forward in integrating digital health services with weight management treatments.
5 min readArch Biopartners Expands LSALT Peptide Trial to US Sites
Arch Biopartners has announced plans to expand its clinical trial of the LSALT peptide into the United States. The move extends the company's research into the peptide's potential therapeutic applications. Details of the expansion were reported on August 12, 2026.
5 min read
Why Big Pharma Avoids Unapproved Peptide Investments
A recent report from the Australian Financial Review explores why major pharmaceutical companies have not committed funding to unapproved peptides. The article examines the regulatory, scientific, and commercial barriers that keep big pharma on the sidelines. It highlights the cautious approach of the industry toward these compounds.
5 min readRetatrutide and Erectile Dysfunction: What the Evidence Shows
A report titled "Does Retatrutide Cause Erectile Dysfunction?" from FC Bayern, dated August 1, 2026, addresses a common question about the investigational obesity drug. The article, categorized under Clinical Trials, examines whether retatrutide is linked to erectile dysfunction. It provides a focused overview of the concern without presenting new clinical data.
5 min readClinical Trial Results: New Weight Loss Pill Beats Oral Semaglutide in Major Trial
A new once-daily weight-loss pill, orforglipron, reportedly outperformed oral semaglutide in a major clinical trial, delivering greater weight loss and blood sugar improvements. The tablet offers a more convenient alternative to injectable drugs like Ozempic and Wegovy, with no need for refrigeration or meal timing, and could expand global access due to lower manufacturing costs.
4 min read
Amylin Shows Promise as Diabetes and Obesity Treatment
Amylin is being investigated as a novel therapy for diabetes and obesity, according to a Medscape report published July 6, 2026. The article highlights the potential of amylin-based treatments to address metabolic conditions. This development comes amid growing interest in new peptide-based therapies for weight management and glycemic control.
3 min readPositive Phase 2 Clinical Trial Results for New Oral GLP-1 in Obesity Research
Early reports indicate positive Phase 2 clinical trial results for a new oral GLP-1 receptor agonist targeting obesity. This article reviews the reported findings, their significance for peptide research, and what they may mean for future treatment options.
4 min readRetatrutide Clinical Trial Results: Phase III TRIUMPH Data Shows Significant Weight Loss
Early reports from the Phase III TRIUMPH-1 trial suggest retatrutide, a novel triple agonist, has delivered substantial weight loss outcomes. These retatrutide clinical trial results indicate a potential shift in obesity treatment research, though full data analysis is pending.
4 min readRetatrutide Phase III TRIUMPH-1 Results: Unprecedented Weight Loss Reported at ADA26
Early reports from the American Diabetes Association 2026 meeting suggest retatrutide delivered unprecedented weight loss in the Phase III TRIUMPH-1 trial. Researchers and industry professionals are closely watching these retatrutide clinical trial results for implications in obesity and metabolic disease treatment.
4 min read
Time to Minimum C-Peptide May Predict T1D Treatment Response
A new study suggests that the time it takes for residual C-peptide levels to reach a minimum after diagnosis may serve as a predictor of treatment efficacy in type 1 diabetes. The finding could help clinicians identify patients most likely to benefit from early interventions.
2 min readOral Orforglipron Maintains Weight Loss After Injectables in ATTAIN-MAINTAIN Trial
The ATTAIN-MAINTAIN trial finds that oral orforglipron helps patients maintain weight loss gained from injectable obesity drugs. This study highlights orforglipron's role in post-treatment weight control. Oral administration provides a follow-up option after injectables.
1 min readECO 2026: ATTAIN-MAINTAIN Trial Shows Orforglipron in Sustained Weight Loss
The ATTAIN-MAINTAIN trial at ECO 2026 demonstrates orforglipron's effectiveness for sustained weight loss. This presentation highlights the drug's specific role in weight management. Findings from the trial focus on achieving and keeping weight loss over time.
2 min readSurvodutide Shows Renal and Metabolic Gains in DKD Mouse Model at ECO 2026
Researchers presented data at the European Congress on Obesity (ECO) on survodutide's effects in a mouse model of advanced diabetic kidney disease (DKD). The drug improved kidney injury markers like albuminuria and glomerulosclerosis, along with metabolic measures such as body weight and glucose levels. These results suggest potential for broader applications if confirmed in human studies.
2 min read
Orforglipron Maintains Weight Loss After Stopping Injections
Results from the ATTAIN-MAINTAIN trial show that orforglipron pills helped patients keep most of their weight loss after stopping injectable tirzepatide or semaglutide. Participants switching to the daily oral GLP-1 maintained far more weight reduction than those on placebo. The study involved 376 US patients previously treated with injections for over a year.
3 min readAdults Retain Most Weight Loss After Switching to Foundayo
Adults who switched from an injectable drug to Foundayo maintained the majority of their weight loss. This outcome shows patients can preserve a substantial portion of prior weight reduction following the change in treatment. The results point to Foundayo's role in sustaining weight management after injectable use.
2 min read
Eli Lilly Suggests Low-Dose Zepbound and Foundayo for Weight Loss Maintenance
Eli Lilly indicates that a lower dose of its obesity drug Zepbound may serve as a safe, effective, and possibly less expensive way to maintain weight loss. This comes from new data in a clinical trial. The company also mentions Foundayo as another option for weight maintenance.
2 min readAstraZeneca $800M Drug Misses Phase 3 Goal on Immunogenicity
AstraZeneca's candidate for a rare endocrine disorder showed reduced efficacy in a phase 3 trial due to immunogenicity. The $800 million molecule's response rate did not meet the standard set by Ascendis Pharma's Yorvipath. This outcome affects the company's investment in the prospect.
2 min readStudy: Orforglipron Maintains Most Weight Loss from Injectables
A study demonstrates that patients retain most weight loss from injectable obesity drugs after switching to orforglipron. This research confirms the medication's role in preserving treatment outcomes. The findings support transition strategies for obesity management.
2 min readOral Orforglipron Effective for Obese Older Adults
Clinical trial results show oral orforglipron is effective in older adults with obesity. The medication works well when taken by mouth in this population. This finding focuses on obesity treatment needs for seniors. Orforglipron provides effectiveness specifically for older adults facing obesity.
1 min readOrforglipron and Probiotic Aid Weight Loss Maintenance in Obesity
Two independent clinical trials demonstrate that the drug orforglipron helps patients with obesity keep their weight loss. A probiotic supplement provides similar benefits for weight maintenance in this group. These results highlight options for sustaining weight reduction.
2 min readOrforglipron Tested in Phase 3b ATTAIN-MAINTAIN Weight Trial
A double-blind, randomized phase 3b trial called ATTAIN-MAINTAIN examined orforglipron for maintaining body weight reduction. The study appears in Nature. This research focuses on sustaining weight loss achieved earlier.
2 min readDaily Pill Could Tackle Dreaded Ozempic Rebound
A daily pill could serve as the answer to the dreaded Ozempic rebound. Retatrutide and survodutide appear in this context within clinical trials. This approach targets a common challenge after Ozempic treatment.
2 min readOrforglipron May Transform Obesity Treatment Approach
Pharmacy Times published an article questioning if Orforglipron could permanently alter obesity treatment.It falls under the Clinical Trials category.
2 min readOther categories